Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,624 across all filing types
Latest filing 2023-11-22 Regulatory Filings
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - THE FULL APPROVAL OF TELITACICEPT FOR THE TREATMENT OF ADULT PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS BY NMPA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by RemeGen Co., Ltd. regarding the full approval of their drug telitacicept by China's National Medical Products Administration (NMPA). It details the clinical trial results, regulatory milestones, and future prospects of the drug. The text is an announcement of a regulatory approval event rather than a financial report, earnings release, or management discussion. It does not contain financial statements, earnings data, or detailed management analysis. It also does not fit into categories like M&A, capital updates, or governance changes. The document is a regulatory announcement about product approval, which aligns best with the Regulatory Filings (RNS) category as a general regulatory announcement that does not fit other specific categories. The document length is about 5,491 characters, which is not extremely short, but the content is clearly an announcement rather than a report or presentation. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-11-22 English
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 21 NOVEMBER 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the poll results from an Extraordinary General Meeting (EGM) held on 21 November 2023. It details the voting outcome on a resolution related to a proposed disposal and mandate to directors. The text references the EGM Notice and Circular but does not contain the full text of the resolution or detailed financial data. The document is relatively short (3505 characters) and serves to officially communicate the voting results rather than the meeting materials or detailed reports. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-11-21 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2023-11-20 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2023-11-20 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2023-11-20 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2023-11-20 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.